Growth Metrics

Plus Therapeutics (PSTV) Total Current Liabilities (2016 - 2025)

Plus Therapeutics has reported Total Current Liabilities over the past 16 years, most recently at $12.3 million for Q4 2025.

  • Quarterly Total Current Liabilities fell 20.82% to $12.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.3 million through Dec 2025, down 20.82% year-over-year, with the annual reading at $12.3 million for FY2025, 20.82% down from the prior year.
  • Total Current Liabilities was $12.3 million for Q4 2025 at Plus Therapeutics, down from $13.6 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $18.8 million in Q2 2024 and troughed at $4.9 million in Q1 2022.
  • The 5-year median for Total Current Liabilities is $10.5 million (2023), against an average of $10.5 million.
  • Year-over-year, Total Current Liabilities skyrocketed 160.03% in 2023 and then plummeted 61.06% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $5.9 million in 2021, then surged by 101.91% to $11.9 million in 2022, then dropped by 9.49% to $10.7 million in 2023, then soared by 44.97% to $15.6 million in 2024, then dropped by 20.82% to $12.3 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Total Current Liabilities are $12.3 million (Q4 2025), $13.6 million (Q3 2025), and $7.3 million (Q2 2025).